

ClearGuard® HD

Antimicrobial Barrier Caps


100 Infection Control Products to Know in 2019¹
 – Becker's Hospital Review

ClearGuard® HD Cap Kills Bacteria Inside the Catheter Hub

- ◆ ClearGuard HD cap is the *first and only* device available for sale in the US that kills infection causing bacteria inside a hemodialysis catheter hub
- ◆ Bloodstream infection (BSI) is a leading cause of hospitalizations and the second leading cause of death in hemodialysis patients²
- ◆ Catheters cause 70% of BSIs³

How it Works

The ClearGuard HD cap features a rod that extends into the hemodialysis catheter hub. The rod and cap threads are coated with chlorhexidine, a well-known broad-spectrum antimicrobial agent, to kill infection-causing microorganisms.



The ClearGuard® HD Difference

	ClearGuard® HD Caps	Standard Caps	Tego® Connector	Tego® + CuroS™
Kills bacteria inside the hub	✓	-	-	-
Kills bacteria on outside of hub	✓	-	-	-
Large randomized, controlled trials in hemodialysis patients	✓	-	-	-
Clinically proven to reduce BSI	✓	-	-	-
Uses chlorhexidine	✓	-	-	-
FDA cleared indication for reduction in BSI	✓	-	-	-

Major Clinical Trials Demonstrate Superiority of ClearGuard HD Caps



JASN CLINICAL RESEARCH www.jasn.org
Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection
Steven M. Brunelli,¹ David B. Van Wyck,² Levi Njord,² Robert J. Ziebol,³ Laurie E. Lynch,³ and Douglas P. Killion³
¹DaVita Clinical Research, Minneapolis, Minnesota; ²DaVita, Inc., Denver, Colorado; and ³Pursuit Vascular, Inc., Maple Grove, Minnesota
Editorial from Dr. Alan Kliger*

ClearGuard HD vs. Tego + Curois



J Am Soc Nephrol. 2018; 29:1336-1343


ClearGuard HD caps superior to Tego+Curois with reduction in BSIs of 63-82% across nine analyses

- 13-month, prospective, cluster-randomized, multicenter trial
- 1671 patients accruing >183,000 CVC-days
- 40 centers across the United States



ClearGuard HD vs. Standard Caps

Am J Kidney Dis. 2017; 69(2):220-227



AJKD
Original Investigation
Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap
Jeffrey L. Hymes, MD,¹ Ann Mooney, MSN, RN, CNN,² Carly Van Zandt, MS,² Laurie Lynch, PhD,³ Robert Ziebol, BS,³ and Douglas Killion, MBA³
2017 EDITORS' CHOICE AWARD
Background: The rate of bloodstream infection (BSI) is disproportionately high in hemodialysis (HD)

ClearGuard HD caps superior to standard hemodialysis caps with reduction in BSIs of 56-69%

- 12-month, prospective, cluster-randomized, multicenter trial
- 2470 patients accruing 350,000 CVC-days
- 40 centers across the United States

¹Becker's Hospital Review
<https://www.beckershospitalreview.com/lists/100-infection-control-products-to-know-2019.html>

²United States Renal Data System: 2018 USRDS Annual Data Report: End-stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes & Digestive & Kidney Diseases.

³Nguyen, DB et al. 2017. National Healthcare safety network (NHSN) dialysis event surveillance report for 2014. Clin J Am Soc Nephrol 12, 1139-1146.

ClearGuard is a registered trademark of Pursuit Vascular Inc. Tego is a registered trademark of ICU Medical, Inc. Curois is a trademark of 3M. The ClearGuard HD Antimicrobial Barrier Cap has been shown to be effective at reducing microbial colonization in hemodialysis catheter hubs and to reduce the incidence of CLABSI in hemodialysis patients with catheters. See the Instructions for Use for full indications. Rx Only.



6901 E Fish Lake Road, Suite 166
Maple Grove, MN 55369

612-424-9006 | info@pursuitvascular.com
www.pursuitvascular.com

